Filing Flows › Volitionrx (VNRX) › Q3 2025
Volitionrx (VNRX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Volitionrx (VNRX) reported revenue of $627K for the third quarter 2025 (Q3 2025), +32% from a year earlier and +54% from the quarter before. Operating margin was -813.2%, net loss $5.4M (862.4% of revenue).
Volitionrx, Q3 2025: revenue $627K (+32% year over year), operating margin -813.2%, net loss $5.4M, operating cash flow −$3.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $627K | +54% | +32% |
| Operating profit | −$5.1M | — | — |
| Net earnings | −$5.4M | — | — |
| Operating cash flow | −$3.6M | — | — |
What changed
Revenue was $627K in Q3 2025, up 32% year over year and up 54% from the previous quarter.
Operating costs exceeded revenue by $5.1M, an operating margin of -813.2%. Total costs fell 10% while revenue rose 32%. The fastest-growing cost line was General & admin (+37%). The quarter ended with a net loss of $5.4M, narrower than the previous quarter's $6.3M loss. Minority interests bore $31K of it: to shareholders the quarter was a loss of $5.4M.
Operating cash flow was −$3.6M. Non-cash charges added back $248K of depreciation and amortization and $609K of share-based compensation. Working capital and other items added $922K.
Questions
What was Volitionrx's revenue in the third quarter 2025?
Volitionrx (VNRX) reported revenue of $627K for the third quarter 2025 (Q3 2025), +32% from a year earlier and +54% from the quarter before.
Was Volitionrx profitable in the third quarter 2025?
Operating loss was $5.1M (-813.2% of revenue) and net loss $5.4M.
Source: Volitionrx 10-Q on SEC EDGAR.